Method to achieve extended expression of DNA infused into liver
AssigneeImmusoft Corporation
InventorsR. Scott McIvor, Perry B. Hackett, Jason Bell, Myra Christine Urness-Rusten, Elena Aronovich, David W. Hunter
Life of this patent
Estimating the term…
Abstract
Materials and methods for treating a patient to express a therapeutic agent comprising administering a Kupffer cell-suppressing substance in combination with a vehicle for introducing, into the patient, an exogenous nucleic acid comprising a sequence for expression of the agent.
Claims14
A method of treating a human patient to express a therapeutic agent, comprising administering a Kupffer cell-suppressing substance in combination with a vehicle for introducing, into the human patient, an exogenous nucleic acid comprising a sequence for expression of the agent, wherein the Kupffer cell-suppressing substance, upon dissolution in aqueous solution, comprises a free gadolinium(III) ion,
- wherein the method comprises administering the Kupffer cell-suppressing substance within 24 hours prior to administering the exogenous nucleic acid and also at a time between 1 and 10 days after administering the exogenous nucleic acid.
A method of treating a human patient for expression of a gene comprising administering, to a human, an exogeneous nucleic acid that expresses the gene in combination with a Kupffer cell-suppressing substance that comprises a gadolinium atom that is free of chelating agents that form three or more coordinate bonds with the gadolinium atom,
- wherein the method comprises administering the Kupffer cell-suppressing substance within 24 hours prior to administering the exogenous nucleic acid and also at a time between 1 and 10 days after administering the exogenous nucleic acid.
Dependencies are inferred from the claim text.